The 6th World Symposium on Pulmonary Hypertension: what's old is new.
The 6th World Symposium on Pulmonary Hypertension: what's old is new.
复制标题
DOI：
10.12688/f1000research.18811.1
复制
发表时间：
2019-01-01
期刊：
影响因子：
--
通讯作者：
de Jesus Perez, Vinicio A
中科院分区：
文献类型：
--
作者：
Condon, David F;Nickel, Nils P;de Jesus Perez, Vinicio A
2018年2月，第六届世界肺动脉高压研讨会（WSPH）汇集了来自各个学科的专家，回顾了过去5年来肺动脉高压领域最相关的临床和科学进展。基于不同工作组成员的仔细审查和讨论，对各种形式PH的血流动力学定义进行了重大修订，并将新的基因添加到与肺动脉高压（PAH）和肺静脉闭塞性疾病相关的遗传标记列表中。此外，鼓励使用风险分层工具作为一种策略，通过早期实施PAH治疗来降低PAH患者一年死亡风险。虽然医学界成员仍在争论一些拟议的改变，但新的WSPH指南提倡早期诊断和开始联合治疗，以降低PH患者的死亡率和改善生活质量。
In February 2018, the 6th World Symposium on Pulmonary Hypertension (WSPH) brought together experts from various disciplines to review the most relevant clinical and scientific advances in the field of PH over the last 5 years. Based on careful review and discussions by members of the different task forces, major revisions were made on the hemodynamic definition for various forms of PH and new genes were added to the list of genetic markers associated with pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease. In addition, the use of risk stratification tools was encouraged as a strategy to reduce one-year mortality risk in PAH patients through early implementation of PAH therapies. While members of the medical community are still debating some of the proposed changes, the new WSPH guidelines advocate early diagnosis and initiation of combination therapy to reduce mortality and improve quality of life in patients with PH.